Dr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418) @NEJMgroup
Dr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418) @NEJMgroup
Uploaded April 2026 | Updated September 2026, 1 week ago
This video in our partnership with @DGlaucomflecken explains a clinical trial evaluating the clinical efficacy of tecovirimat against human clade II mpox.

View the Original Article for free: https://nej.md/DrG38

#infectiousdiseases #medicaleducation #nejm
Dr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418)Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905)OpenAIโ€™s Karan Singal on HealthBench and the Future of Medical AIIntention to Treat: The Race Equation (Teaser)Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF)NEJM Outbreaks Updates โ€” Andes HantavirusNEJM This Week โ€” August 13, 2026Dr. Glaucomflecken Explains: Transdermal Estradiol in Prostate CancerBiDil โ€” The Story of the Black PillImage Challenge โ€” May 7, 2026High-Reliability Organizing: Refreshing a Proven Framework for Modern Health Care ChallengesClinical Practice: Prevention and Treatment of Peanut Allergy
NEJM Group |

Dr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER